Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman

This article was originally published in The Gray Sheet

Executive Summary

FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval
Advertisement

Related Content

FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance
FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
Acorn Releases CorCap Pivotal Trial Results, Anticipates 2005 Panel Review
Acorn Releases CorCap Pivotal Trial Results, Anticipates 2005 Panel Review
Improved Postmarket Compliance Requires FDA, Industry Attention – Phillips
Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
Advertisement
UsernamePublicRestriction

Register

MT020559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel